IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/35, 35/78 — A1

(11) International Publication Number: **WO 99/48496**

(43) International Publication Date: 30 September 1999 (30.09.99)

(21) International Application Number: PCT/AU99/00222

(22) International Filing Date: 26 March 1999 (26.03.99)

(30) Priority Data:
PP 2607 26 March 1998 (26.03.98) AU

(71) Applicant *(for all designated States except US)*: NOVOGEN RESEARCH PTY. LTD. [AU/AU]; 140 Wicks Road, North Ryde, NSW 2113 (AU).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: KELLY, Graham, Edmund [AU/AU]; 47 Coolawin Road, Northbridge, NSW 2063 (AU). HUSBAND, Alan, James [AU/AU]; 13 Marana Crescent, Northbridge, NSW 2063 (AU).

(74) Agents: STEARNE, Peter, Andrew et al.; Davies Collison Cave, Level 10, 10 Barrack Street, Sydney, NSW (AU).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: THERAPY OF ESTROGEN–ASSOCIATED DISORDERS

(57) Abstract

A method for the treatment, prophylaxis, amelioration or prevention of disorders associated with abnormally high activity of steroidal estrogens, which includes administering to a human subject a composition comprising an isoflavone–containing extract of clover or chick peas, said extract comprising primarily biochanin, or a ratio of biochanin to one or more of the isoflavones from the group formononetin, daidzein and genistein in the range of from about 2:1 to about 5:1, optionally in association with one or more pharmaceutically acceptable carriers, excipients, auxiliaries and/or diluents is described. Also described are compositions and uses comprising the isoflavone containing extracts.